The Effect of Comprehensive Rehabilitation Program Plus Chemotherapy on Quality of Life in Patients with Postoperative Non-small-cell Lung Cancer: Study Protocol of a Multicenter Randomized Clinical Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2020 Apr 5

PMID 32245480

Citations 4

Authors

Jialin Yao

Lijing Jiao

Yiqing Yao

Yan Lu

Jun Shi

Jiaqi Li

Peiqi Chen

Ling Xu

Yabin Gong

Affiliations

Soon will be listed here.

Abstract

Background: Comprehensive rehabilitation therapy based on traditional Chinese medicine (TCM) has been widely applied in various cancer treatments in China. Thus far, Chinese herbal medicine (CHM) has been shown effective in reducing the adverse effects of chemotherapy and improving the quality of life (QoL) during chemotherapy. The purpose of the present study is to compare the effects of CHM plus Liu Zi Jue (LZJ) exercises with CHM plus rehabilitation education and with placebo plus rehabilitation education in patients who have undergone complete resection for nonsmall-cell lung cancer (NSCLC) followed by postoperative adjuvant chemotherapy.

Methods And Design: A multicenter, randomized clinical trial will be performed with 354 stage Ib-IIIa NSCLC patients in five centers in China. Patients satisfying the inclusion criteria will be randomly divided into three groups according to a 1:1:1 ratio: intervention group A (IGA), intervention group B (IGB), and control group (CG). Each group will receive adjuvant platinum-based doublet chemotherapy for a total of four cycles. IGA participants will receive chemotherapy combined with CHM and LZJ exercises, IGB participants will receive chemotherapy combined with CHM and rehabilitation education, and CG participants will receive chemotherapy combined with placebo and rehabilitation education. The herbal treatment patients will be given granules daily and LZJ exercises will be performed four times per week during chemotherapy. The primary outcome is QoL, which will be assessed with the European Organization for Research and Treatment of Cancer (EORTC)-QLQ-C43 scale in each cycle. The secondary outcomes include the 2-year disease-free survival rate, disease-free survival, TCM symptoms, tumor markers, safety, and adverse events. After treatment, the patients will be followed up every 3 months within 2 years and every 6 months after 2 years until disease recurrence and/or metastasis.

Discussion: Our previous study reported that CHM in combination with chemotherapy could lower the overall incidence of adverse events but increased digestive and gastrointestinal side effects compared with chemotherapy alone in postoperative NSCLC patients. This study will lay a foundation for the effectiveness of chemotherapy with or without a comprehensive rehabilitation program for QoL in patients with postoperative NSCLC.

Trial Registration: ClinicalTrials.gov, NCT03372694. Retrospectively registered on 17 December 2018.

Citing Articles

Are Published Cancer Care Trial Protocols With Traditional Chinese Medicine Interventions Concordant With SPIRIT-TCM Extension 2018? A Scoping Review on Published Trial Protocols Between 2019 and 2022.

Lai H, Yang P, Wang X, Lim D, Lam A, Shi Y Integr Cancer Ther. 2024; 23:15347354231223966.

PMID: 38291957 PMC: 10832418. DOI: 10.1177/15347354231223966.

Luteolin inhibits A549 cells proliferation and migration by down-regulating androgen receptors.

Li X, Tang Y, Liang P, Sun M, Li T, Shen Z Eur J Med Res. 2023; 28(1):353.

PMID: 37716981 PMC: 10504720. DOI: 10.1186/s40001-023-01302-4.

Costs of traditional Chinese medicine treatment for inpatients with lung cancer in China: a national study.

Nie H, Han Z, Nicholas S, Maitland E, Huang Z, Chen S BMC Complement Med Ther. 2023; 23(1):5.

PMID: 36624405 PMC: 9827714. DOI: 10.1186/s12906-022-03819-3.

Network Pharmacology and Experimental Verification to Explore the Potential Mechanism of Yin-Huo-Tang for Lung Adenocarcinoma Recurrence.

Liu D, Lin S, Li Y, Zhou T, Hu K, Li Q Drug Des Devel Ther. 2022; 16:375-395.

PMID: 35210754 PMC: 8860994. DOI: 10.2147/DDDT.S343149.

References

Bezjak A, Lee C, Ding K, Brundage M, Winton T, Graham B . Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol. 2008; 26(31):5052-9. PMC: 2652099. DOI: 10.1200/JCO.2007.12.6094. View

Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, Brecht M . Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest. 2004; 125(2):439-45. DOI: 10.1378/chest.125.2.439. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Wang Q, Wang S, Jiao L, Zhang R, Zhong Y, Zhang J . Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Curr Oncol. 2017; 24(4):e269-e276. PMC: 5576466. DOI: 10.3747/co.24.3561. View

Bradbury P, Sivajohanathan D, Chan A, Kulkarni S, Ung Y, Ellis P . Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review. Clin Lung Cancer. 2017; 18(3):259-273.e8. DOI: 10.1016/j.cllc.2016.07.002. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Chen S, Flower A, Ritchie A, Liu J, Molassiotis A, Yu H . Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review. Lung Cancer. 2009; 68(2):137-45. DOI: 10.1016/j.lungcan.2009.11.008. View

Chan A, Tetzlaff J, Altman D, Laupacis A, Gotzsche P, Krleza-Jeric K . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013; 158(3):200-7. PMC: 5114123. DOI: 10.7326/0003-4819-158-3-201302050-00583. View

Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R . Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21):3552-9. DOI: 10.1200/JCO.2007.13.9030. View

10.

Cerfolio R, Bryant A . Quality of life after pulmonary resections. Thorac Surg Clin. 2013; 23(3):437-42. DOI: 10.1016/j.thorsurg.2013.05.004. View

11.

Jiao L, Dong C, Liu J, Chen Z, Zhang L, Xu J . Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients. Sci Rep. 2017; 7:46524. PMC: 5402288. DOI: 10.1038/srep46524. View

12.

. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311(7010):899-909. PMC: 2550915. View

13.

He J, Shen J, Yang C, Jiang L, Liang W, Shi X . Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015; 94(22):e903. PMC: 4616365. DOI: 10.1097/MD.0000000000000903. View

14.

Wu W, Liu X, Li P, Li N, Wang Z . Effect of Liuzijue Exercise Combined with Elastic Band Resistance Exercise on Patients with COPD: A Randomized Controlled Trial. Evid Based Complement Alternat Med. 2018; 2018:2361962. PMC: 6016162. DOI: 10.1155/2018/2361962. View

15.

Xiao C, Zhuang Y . Efficacy of Liuzijue Qigong in Individuals with Chronic Obstructive Pulmonary Disease in Remission. J Am Geriatr Soc. 2015; 63(7):1420-5. DOI: 10.1111/jgs.13478. View

16.

Detterbeck F, Chansky K, Groome P, Bolejack V, Crowley J, Shemanski L . The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2016; 11(9):1433-46. DOI: 10.1016/j.jtho.2016.06.028. View

17.

Arbane G, Tropman D, Jackson D, Garrod R . Evaluation of an early exercise intervention after thoracotomy for non-small cell lung cancer (NSCLC), effects on quality of life, muscle strength and exercise tolerance: randomised controlled trial. Lung Cancer. 2010; 71(2):229-34. DOI: 10.1016/j.lungcan.2010.04.025. View

18.

Arbane G, Douiri A, Hart N, Hopkinson N, Singh S, Speed C . Effect of postoperative physical training on activity after curative surgery for non-small cell lung cancer: a multicentre randomised controlled trial. Physiotherapy. 2014; 100(2):100-7. DOI: 10.1016/j.physio.2013.12.002. View

19.

Moller A, Sartipy U . Predictors of postoperative quality of life after surgery for lung cancer. J Thorac Oncol. 2011; 7(2):406-11. DOI: 10.1097/JTO.0b013e3182398e82. View

20.

Gridelli C, Langer C, Maione P, Rossi A, Schild S . Lung cancer in the elderly. J Clin Oncol. 2007; 25(14):1898-907. DOI: 10.1200/JCO.2006.10.3085. View